NCT00369941View on ClinicalTrials.gov

A Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA (0518-021 EXT)

PHASE3CompletedINTERVENTIONAL

Enrollment

566

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

May 31, 2009

Study Completion Date

February 29, 2012

Conditions

HIV Infections

Interventions

DRUG

MK-0518

400 mg MK-0518 tablet taken by mouth (PO) twice a day (b.i.d.) for up to 240 weeks

DRUG

Comparator: efavirenz

600 mg efavirenz tablet taken by mouth (PO) every night (q.h.s.) for up to 240 weeks

DRUG

Comparator: Truvada

One tablet Truvada once a day (q.d.) for up to 240 weeks (one tablet contains 200 mg emtricitabine and 300 mg tenofovir)

DRUG

Comparator: Placebo to MK-0518

Placebo to MK-0518 PO b.i.d., taken for up to 240 weeks

DRUG

Comparator: Placebo to efavirenz

Placebo to efavirenz PO every night (q.h.s.), taken for up to 240 weeks

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00369941 - A Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA (0518-021 EXT) | Biotech Hunter | Biotech Hunter